Related Experiment Video
Updated: Sep 3, 2025
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy]
Lin Jiang1, Jingbo Zhang1, Jiaqi Hu1
1Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China.
Abstract:
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC. .
Insights
Proteolysis targeting chimeria (PROTAC) offers a novel therapeutic strategy for non-small cell lung cancer (NSCLC). This approach degrades target proteins, showing promise for treating resistant and previously undruggable mutations.
Area of Science:
- Biochemistry
- Oncology
- Drug Discovery
Background:
- Traditional small molecule inhibitors face limitations in treating non-small cell lung cancer (NSCLC).
- Acquired drug resistance and undruggable targets pose significant challenges in NSCLC therapy.
Purpose of the Study:
- To explore the potential of Proteolysis Targeting Chimeria (PROTAC) technology in degrading key oncogenic proteins in NSCLC.
- To evaluate PROTACs as a therapeutic strategy for overcoming drug resistance and targeting previously undruggable mutations in NSCLC.
Main Methods:
- Utilizing the ubiquitin-proteasome pathway to achieve targeted protein degradation.
- Investigating PROTAC efficacy against common NSCLC mutation targets like KRAS, EGFR, and ALK in preclinical models.
Main Results:
- PROTAC technology has demonstrated successful degradation of KRAS, EGFR, and ALK proteins in preclinical NSCLC studies.
- PROTACs exhibit unique event-driven advantages over traditional inhibitors.
Conclusions:
- PROTACs represent a promising new therapeutic strategy for NSCLC treatment.
- This approach holds potential for overcoming acquired drug resistance and targeting undruggable mutations in NSCLC.
